Human leukocyte antigen class I and class II alleles are associated with susceptibility and resistance in borderline leprosy patients from Southeast Brazil

BMC Infectious Diseases

Jane Tomimori²  Somei Ura¹  Maria Esther Salles Nogueira³  Elaine Valim Camarinha Marcos⁴  Fabiana Covolo de Souza-Santana⁴ 

[1] Department of Education and Research, Instituto Lauro de Souza Lima, Rod. Cte João Ribeiro de Barros, km 225/26, Bauru CEP: 17039-800, SP, Brazil;Department of Dermatology, Federal University of São Paulo, UNIFESP, Av. Borges Lagoa, 598, São Paulo CEP: 04038-000, SP, Brazil;Immunology Laboratory, Instituto Lauro de Souza Lima, Rod. Cte João Ribeiro de Barros, km 225/26, Bauru CEP: 17039-800, SP, Brazil;Immunogenetics Laboratory, Instituto Lauro de Souza Lima, Rod. Cte João Ribeiro de Barros, km 225/26, Bauru CEP: 17039-800, SP, Brazil

关键词: Mycobacterium leprae;    Genetics;    HLA alleles;    Borderline;    Leprosy;   

Others  :  1089844
DOI  :  10.1186/s12879-015-0751-0

 received in 2014-03-17, accepted in 2015-01-12,  发布年份 2015

【 摘 要 】

Background

Evidence suggests that human leukocyte antigen (HLA) alleles influence the host immune response against Mycobacterium leprae. However, the association between HLA alleles and borderline (B) leprosy has not been studied. The aim of this study was to determine whether HLA class I and II molecules are associated with susceptibility or resistance to B leprosy including borderline-tuberculoid (BT), borderline-borderline (BB), and borderline-lepromatous (BL).

Methods

DNA was obtained by the salting-out technique from the blood samples of 202 patients with B leprosy and 478 control subjects. HLA class I (A*, B*, and C* loci) and class II (DRB1* and DQB1* loci) genotypes were determined by polymerase chain reaction amplification and reverse hybridization with sequence-specific oligonucleotide probes and sequence-specific primers.

Results

The case-controlled analysis results showed a significant association between B leprosy and HLA-C*05 (5.94% vs. 14.02%; p = 0.002, OR = 0.38, 95% CI = 0.20–0.73, pc = 0.032) and HLA-DRB1*07 (16.34% vs. 26.77%; p = 0.003, OR = 0.53, 95% CI = 0.3–0.8, pc = 0.039). A protective association was observed between BL leprosy and HLA-DQB1*02 (18.18% vs. 39.53%; p = 0.005, OR = 0.34, 95% CI = 0.15–0.75, pc = 0.025). In reactional patients, a significant association was observed between HLA-B*15 (28.72% vs. 12.76%; p = 0.011, OR = 2.75, 95% CI = 1.30–5.85, pc = 0.352) and predisposition to reversal reaction. Haplotype analysis showed that A*02-B*07-C*07-DRB1*15-DQB1*06 (2.97% vs. 1.04%; p = 0.015) and A*02-B*40-C*03-DRB1*13-DQB1*06 (1.73% vs. 0.10%; p = 0.0011) were associated with susceptibility to the B form. The presence of the HLA-DRB1*02 or HLA-DRB1*03/HLA-DQB1*01 haplotypes in B patients (22.05% vs. 33.0%; p = 0.005) suggested the involvement of these haplotypes in this clinical form of the disease.

Conclusions

The results indicate the involvement of HLA class I and class II molecules in B leprosy and reversal reactions; it also suggest a role for HLA in polarization of the disease in this group of patients.

【 授权许可】

   
2015 de Souza-Santana et al.; licensee BioMed Central.

【 参考文献 】

• [1]Rees RJW: The microbiology of leprosy. In Leprosy. 4th edition. Edited by Hastings RC. Churchil Livingstone, Edinburg; 1994:49-83.
• [2]Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966, 34:255-73.
• [3]Opromolla DVA, Fleury RN: Formas clínicas de la lepra. Anais Congresso Internacional de la Lepra, Cidade do México; 1978.
• [4]Pereira Júnior AC, Gurfinkel AC: Positioning of borderline and indetermined groups in the hanseniasis classification. Hansen Int. 1981, 6:63-70.
• [5]Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL: The continuing challenges of leprosy. Clin Microbiol Rev. 2006, 19:338-81.
• [6]Kumar B, Dogra S, Kaur I: Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis. 2004, 72:125-33.
• [7]Opromolla DVA: Manifestações Clínicas e Reações. In Noções de Hansenologia. 2nd edition. Edited by Opromolla DVA. Centro de Estudos Dr. Reynaldo Quagliato, Brasília; 2000:51-8.
• [8]Ottenhoff THM, Verreck FAW, Hoeve MA, van de Vosse E: Control of human host immunity to mycobacteria. Tuberculosis. 2005, 85:53-64.
• [9]Fitness J, Tosh K, Hill AVS: Genetics of susceptibility to leprosy. Genes Immun. 2002, 3:441-53.
• [10]Petzel-Erler ML: Genetics of the immune response and disease susceptibility. Cienc Cult. 1999, 51:199-211.
• [11]Abbas AK, Linchtman AHL, Pillai S: Cellular and molecular immunology. 6th edition. Sauders Elsevier, Philadelphia; 2010.
• [12]Lagrange P, Abel L: Susceptibilité génétique à la lèpre chez l’homme. Acta Leprol. 1996, 10:11-27.
• [13]Takata H, Sada M, Ozawa S, Sekiguchi S: HLA and mycobacterial infection: increased frequency of B8 in Japanese leprosy. Tissue Antigens. 1978, 11:61-4.
• [14]Chan SH: HLA and skin disease in the Chinese. Ann Acad Med Singapore. 1983, 12:3-5.
• [15]Shankarkumar U, Ghosh K, Badakere S, Mohanty D: Novel HLA Class I Alleles Associated with Indian Leprosy Patients. J Biomed Biotechnol. 2003, 2003:208-11.
• [16]Shankarkumar U: HLA associations in leprosy patients from Mumbai, India. Lepr Rev. 2004, 75:79-85.
• [17]Franceschi DSA, Tsuneto LT, Mazini PS, Sacramento WS, Reis PG, Rudnick CCC, et al.: Class-I human leukocyte alleles in leprosy patients from Southern Brazil. Rev Soc Bras Med Trop. 2011, 44:616-20.
• [18]Alter A, Huong NT, Singh M, Orlova M, Van Thuc N, Katoch K, et al.: Human leukocyte antigen class I region single-nucleotide polymorphisms are associated with leprosy susceptibility in Vietnam and India. J Infect Dis. 2011, 203:1274-81.
• [19]Van Eden W, de Vries RR, Mehra NK, Vaidya MC, D’Amaro J, van Rood JJ: HLA segregation of tuberculoid leprosy: confirmation of the DR2 marker. J Infect Dis. 1980, 141:693-701.
• [20]De Vries RR, Mehra NK, Vaidya MC, Gupte MD, Meera Khan P, Van Rood JJ: HLA-linked control of susceptibility to tuberculoid leprosy and association with HLA-DR types. Tissue Antigens. 1980, 16:294-304.
• [21]Van Eden W, Mehra NK, Vaidya MC, D’Amaro J, Schreuder GM, van Rood JJ: HLA and sporadic tuberculoid leprosy: a population study in Maharashtra, India. Tissue Antigens. 1981, 18:189-94.
• [22]Van Eden W, de Vries RR, D’Amaro J, Schreuder I, Leiker DL, van Rood JJ: HLA-DR-associated genetic control of the type of leprosy in a population from surinam. Hum Immunol. 1982, 4:343-50.
• [23]Visentainer JE, Tsuneto LT, Serra MF, Peixoto PR, Petzl-Erler ML: Association of leprosy with HLA-DR2 in a Southern Brazilian population. Braz J Med Biol Res. 1997, 30:51-9.
• [24]Rani R, Fernandez-Vina MA, Zaheer SA, Beena KR, Stastny P: Study of HLA class II alleles by PCR oligotyping in leprosy patients from north India. Tissue Antigens. 1993, 42:133-7.
• [25]Klatser PR, Janson AM, Thole JE, Buhrer S, Bos C, Soebono H, et al.: Humoral and cellular immune reactivity to recombinant M. leprae antigens in HLA-typed leprosy patients and healthy controls. Int J Lepr Other Mycobact Dis 1997, 65:178-89.
• [26]Gorodezky C, Alaez C, Munguía A, Cruz R, Vazquez A, Camacho A, et al.: Molecular mechanisms of MHC linked susceptibility in leprosy: towards the development of synthetic vaccines. Tuberculosis. 2004, 84:82-92.
• [27]Marcos EVC, de Souza FC, Ura S, Opromolla DVA: Study of the association of HLA antigens and ulcerated type 1 leprotic reaction. An Bras Dermatol. 2000, 75:282-90.
• [28]Kim SJ, Choi IH, Dahlberg S, Nisperos B, Kim JD, Hansen JA: HLA and leprosy in Koreans. Tissue Antigens. 1987, 29:146-53.
• [29]Joko S, Numaga J, Kawashima H, Namisato M, Maeda H: Human leukocyte antigens in forms of leprosy among Japanese patients. Int J Lepr Other Mycobact Dis. 2000, 68:49-56.
• [30]Hegazy AA, Abdel-Hamid IA, Ahmed E-SF, Hammad SM, Hawas SA: Leprosy in a high-prevalence Egyptian village: epidemiology and risk factors. Int J Dermatol. 2002, 41:681-6.
• [31]Vanderborght PR, Pacheco AG, Moraes ME, Antoni G, Romero M, Verville A, et al.: HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun. 2007, 8:320-4.
• [32]Da Silva SA, Mazini PS, Reis PG, Sell AM, Tsuneto LT, Peixoto PR, et al.: HLA-DR and HLA-DQ alleles in patients from the south of Brazil: markers for leprosy susceptibility and resistance. BMC Infect Dis. 2009, 9:134. BioMed Central Full Text
• [33]Zhang F, Liu H, Chen S, Wang C, Zhu C, Zhang L, et al.: Evidence for an association of HLA-DRB1*15 and DRB1*09 with leprosy and the impact of DRB1*09 on disease onset in a Chinese Han population. BMC Med Genet. 2009, 10:133. BioMed Central Full Text
• [34]Joko S, Numaga J, Masuda K, Namisato M, Maeda H: HLA class II alleles and leprosy (Hansen’s disease) classified by WHO-MDT criteria. Nihon Rai Gakkai Zasshi. 1996, 65:121-7.
• [35]Miller EN, Jamieson SE, Joberty C, Fakiola M, Hudson D, Peacock CS, et al.: Genome-wide scans for leprosy and tuberculosis susceptibility genes in Brazilians. Genes Immun. 2004, 5:63-7.
• [36]Zhang F-R, Huang W, Chen S-M, Sun L-D, Liu H, Li Y, et al.: Genomewide association study of leprosy. N Engl J Med. 2009, 361:2609-18.
• [37]Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
• [38]Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 2005, 1:47-50.
• [39]Blackwell JM, Jamieson SE, Burgner D: HLA and infectious diseases. Clin Microbiol Rev. 2009, 22:370-85.
• [40]Gorodezky C, Flores J, Arevalo N, Castro LE, Silva A, Rodriguez O: Tuberculoid leprosy in Mexicans is associated with HLA-DR3. Lepr Rev. 1987, 58:401-6.
• [41]Koçak M, Balci M, Pençe B, Kundakçi N: Associations between human leukocyte antigens and leprosy in the Turkish population. Clin Exp Dermatol. 2002, 27:235-9.
• [42]Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR: Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2011, 39:D913-9.
• [43]Romero M. Estudo de Associação entre o Sistema HLA e a Hanseníase. MsD thesis. Instituto Oswaldo Cruz; 2010. p. 101
• [44]Motta PMF, Cech N, Fontan C, Giménez MF, Lodeiro N, Marinic K, et al.: Role of HLA-DR and HLA-DQ alleles in multibacillary leprosy and paucibacillary leprosy in the province of Chaco (Argentina). Enferm Infecc Microbiol Clin. 2007, 25:627-31.
• [45]Van Eden W, Gonzalez NM, de Vries RR, Convit J, van Rood JJ: HLA-linked control of predisposition to lepromatous leprosy. J Infect Dis. 1985, 151:9-14.
• [46]Ottenhoff TM, Converse G, De Vries R: HLA Antigens and Neural Reversal Reaction in Ethiopian Boderline Tuberculoid Leprosy Patients. Int JLeprosy. 1987, 55:261-6.